# Ian E. Krop

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ian-e-krop/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,251 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 101 |
| i10-index | 268 |
| Last Known Institution | Yale Cancer Center |
| OpenAlex ID | https://openalex.org/A5032785430 |
| ORCID iD | https://orcid.org/0000-0002-6380-5944 |
| Works | 881 |

## Researcher papers

- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer](https://scholariq.org/papers/response-and-resistance-to-bet-bromodomain-inhibitors-in-triple-negative-breast/)
- [Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](https://scholariq.org/papers/molecular-heterogeneity-and-response-to-neoadjuvant-human-epidermal-growth/)
- [Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/trastuzumab-deruxtecan-versus-treatment-of-physician-s-choice-in-patients-with/)
- [Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant](https://scholariq.org/papers/heterogeneity-and-clinical-significance-of-esr1-mutations-in-er-positive/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)
- [進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)](https://scholariq.org/papers/eso-esmo-abc-4/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Yale Cancer Center](https://scholariq.org/institutions/yale-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.